Answers are grounded in this paper and cite their sources.
The early diagnosis of biliopancreatic cancers, including cholangiocarcinoma (CCA) and pancreatic ductal adenocarcinoma (PDAC), remains challenging because currently available serum biomarkers have limited diagnostic accuracy. Bile acids are bioactive signaling molecules implicated in carcinogenesis and may reflect disease-specific alterations within the biliary microenvironment. We aimed to characterize biliary bile acid profiles in patients with PDAC and CCA and evaluate their diagnostic potential. Bile samples were prospectively collected from the common bile duct during endoscopic retrograde cholangiopancreatography (ERCP) in 71 individuals, including noncancer controls (CTRL, n = 41), patients with PDAC ( n = 14), and patients with CCA ( n = 16). Quantitative bile acid profiling was performed with ultra-performance liquid chromatography‒tandem mass spectrometry (UPLC‒MS‒MS/MS). Random forest, stability selection, least absolute shrinkage and selection operator, and elastic net algorithms were used as feature-selection methods to identify diagnostic bile acid signatures, which were evaluated using five-fold cross-validated receiver operating characteristic analysis. PDAC was associated with higher total and primary bile-acid concentrations than CCA, including higher cholic acid concentrations. Compared with controls, CCA was associated with lower total secondary bile-acid concentrations ( p = 0.009), including lower deoxycholic acid ( p = 0.013), lithocholic acid ( p = 0.021), and ursodeoxycholic acid ( p = 0.023) concentrations. After adjustment for bilirubin and alkaline phosphatase, glycocholic acid, taurochenodeoxycholic acid, and taurohyocholic acid were selected by all four feature-selection methods. Their combined model achieved a cross-validated area under the curve of 0.85 (95% CI, 0.79–0.90), compared with 0.67 (95% CI, 0.58–0.76) for CA19-9 and 0.61 (95% CI, 0.51–0.71) for CEA. A separate bile-acid model distinguished CCA from PDAC with an area under the curve of 0.87 (95% CI, 0.72–0.99), 85.7% sensitivity, and 87.5% specificity. CCA and PDAC patients exhibit distinct biliary bile acid profiles. Bile acid signatures identified after adjustment for cholestasis may complement conventional serum biomarkers during ERCP-based evaluation of indeterminate biliary strictures.
No takes yet. Share an insight, caveat, or question.
Arif et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: